Valuation : Quest PharmaTech Inc.

Market Cap 33.83L 24.4L 20.95L 19.61L 17.96L 23Cr 33.92L 2.32Cr 90.77L 12Cr 91.61L 89.63L 39Cr P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 43.68L 31.51L 27.05L 25.32L 23.19L 30Cr 43.81L 3Cr 1.17Cr 15Cr 1.18Cr 1.16Cr 50Cr EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
3 months-42.86%
6 months-33.33%
Current year-42.86%
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.07
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Date Insider Type Main position Quantity % Market Cap.
12/12/25 OtherCompany 0 0%
21/10/25 Other

Chief Executive Officer

10,00,000 0.5913%
21/10/25 Other

Chief Executive Officer

3,00,000 0.1774%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-50.00%-71.43% 24.36L
+0.10%+0.44%+2.80%+23.74% 5.1TCr
+2.54%+3.83%+477.94%+581.49% 4.62TCr
-0.69%+0.98%+24.20%+84.46% 4.27TCr
+0.32%+2.39%+38.86%+18.21% 4.3TCr
-2.27%-3.02%+14.22%+51.50% 3.35TCr
-0.77%+0.62%+30.19%+135.59% 1.73TCr
-0.26%-2.12% - - 1.64TCr
+0.25%+0.25%+12.03%+28.88% 1.47TCr
+1.13%+2.30%+83.13%+50.00% 1.41TCr
Average +0.15%+1.20%+70.37%+100.27% 2.79TCr
Weighted average by Cap. +0.27%+1.16%+103.87%+143.44%

Financials

2025 2026
Net sales - -
Net income -18.01L -12.99L -11.15L -10.44L -10L -12Cr -18.06L -1.24Cr -48.33L -6.25Cr -48.78L -47.73L -21Cr 49.98L 36.06L 30.95L 28.98L 26.53L 34Cr 50.13L 3.43Cr 1.34Cr 17Cr 1.35Cr 1.32Cr 57Cr
Net Debt 8L 6L 5L 5L 4L 5.48Cr 8L 54.57L 21.33L 2.76Cr 21.53L 21.06L 9.14Cr 10L 7L 6L 6L 5L 6.79Cr 10L 67.66L 26.45L 3.42Cr 26.69L 26.12L 11Cr
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
27/26/27 CA$0.0200 0.00% 10,000